Innovative Findings on Lecanemab at Upcoming CTAD Conference
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai is set to present pivotal findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease (CTAD) conference. This event, scheduled for December, focuses on critical advancements in Alzheimer's treatment. Researchers will reveal insights into long-term therapy benefits, including estimated time savings over a decade, and safety aspects associated with subcutaneous initiation dosing of lecanemab.
Key Oral Presentations
The CTAD conference will feature key presentations that provide fresh analyses and findings:
Continued Treatment Insights
On December 2nd, new analyses discussing the health benefits of continued lecanemab therapy will be presented. This session will highlight the expected time saved over ten years of lecanemab treatment based on Phase 3 clinical data.
Subcutaneous Initiation Dosing
A late-breaking symposium on December 3rd will delve into the potential advantages of initiating lecanemab treatment through subcutaneous dosing. This discussion will encompass pharmacokinetic aspects and safety results.
Real-World Experiences Shared
A presentation scheduled for December 4th will share findings from an interim analysis of a post-marketing observational study conducted in Japan, focusing on the real-world experience of patients treated with lecanemab.
Impact on Soluble Amyloid-Beta
On December 2nd, a separate presentation will investigate how lecanemab influences soluble amyloid-beta (A?) protofibrils, showcasing evidence drawn from the Clarity AD clinical trial.
Posters Featuring Lecanemab Research
In addition to oral presentations, numerous poster presentations will provide further insights into lecanemab:
Characterizing Enrollment Patterns
A poster scheduled for December 1st and 2nd will focus on patterns of enrollment in a preclinical Alzheimer's disease trial, discussing factors affecting participation.
Stability and Improvement Studies
Another notable poster will explore how lecanemab contributes to stability and improvement in early Alzheimer's disease based on a retrospective real-world study, also scheduled for December 1st and 2nd.
Evaluation of Long-Term Outcomes
A compelling poster presentation will evaluate the long-term benefits of lecanemab for patients with low baseline amyloid levels, estimated based on time saved throughout the course of treatment.
Patient Acceptability of Autoinjectors
This session will discuss the acceptability of using an autoinjector for the subcutaneous delivery of lecanemab among patients and their caregivers.
BioArctic and Eisai Collaboration
Lecanemab is the culmination of a longstanding partnership between BioArctic and Eisai. This monoclonal antibody was originally crafted based on Professor Lars Lannfelt's groundbreaking discovery concerning the Arctic mutation in Alzheimer's. Eisai leads the way in clinical studies, market approval submissions, and the commercialization efforts for lecanemab globally.
In 51 countries, lecanemab has received approval, with research continuing in 9 additional markets. The regimen involves treatment every two weeks for the initial 18 months, transitioning to intravenous (IV) administration every four weeks thereafter. In the United States, lecanemab Iqlik™ has gained approval for subcutaneous delivery utilizing an autoinjector.
About BioArctic AB
BioArctic AB (publ) specializes in cutting-edge treatments aimed at delaying or halting the progression of neurodegenerative disorders. The company is known for developing Leqembi® (lecanemab) – the first drug validated to slow down the deterioration associated with early Alzheimer's. Beyond lecanemab, BioArctic engages in in-depth research involving antibodies targeting Parkinson's disease, ALS, and various advancements in Alzheimer's treatment methodologies.
Frequently Asked Questions
What is the significance of the CTAD conference for lecanemab?
The CTAD conference presents an opportunity to showcase groundbreaking findings and peer-reviewed data on lecanemab, affecting the future of Alzheimer's treatments.
When are the key presentations scheduled during the CTAD conference?
Key presentations will occur on December 2nd to 4th, focusing on treatment insights, real-world experiences, and new dosing methods.
How does lecanemab differ from other Alzheimer's treatments?
Lecanemab is a monoclonal antibody that targets amyloid-beta protofibrils, which are associated with cognitive decline, and is approved in multiple countries for use in Alzheimer's patients.
What role does BioArctic play in the development of lecanemab?
BioArctic collaborates with Eisai on the research, development, and commercialization of lecanemab, maintaining commercialization rights in the Nordic region.
Are there ongoing studies about lecanemab?
Yes, several studies, such as the AHEAD 3-45 trial, focus on lecanemab's efficacy in preclinical Alzheimer's patients, and new studies continue to emerge.
